



BSE : 500257	NSE: Lupin	REUTERS: LUPN.BO	BLOOMBERG: LPC IN
--------------	------------	------------------	-------------------

## **Lupin launches Generic SEROQUEL® Tablets Receives final FDA Approval for its Generic SEROQUEL® Tablets**

**Mumbai / Baltimore, March 28, 2012:** Pharma major, Lupin Ltd., announced today that it has received final approval for its Quetiapine Fumarate Tablets 25 mg, 50 mg, 100 mg, 200 mg, 300 mg and 400 mg strengths from the U.S. Food and Drug Administration (FDA).

Quetiapine Fumarate Tablets is AB rated generic equivalent of AstraZeneca's SEROQUEL® Tablets (25, 50, 100, 200, 300 & 400 mg). Lupin has already commenced shipping product.

Quetiapine is a psychotropic agent, indicated for treatment of Schizophrenia & acute treatment of manic episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. It is also indicated as monotherapy for the acute treatment of depressive episodes associated with bipolar disorder and for the maintenance treatment of bipolar I disorder, as an adjunct to lithium or divalproex.

AstraZeneca's SEROQUEL® Tablets had sales of USD 4.6 billion as per IMS Health, December 2011.

### **About Lupin Limited**

Headquartered in Mumbai, India, Lupin is an innovation led transnational pharmaceutical company producing a wide range of generic and branded formulations and APIs. The Company today has significant presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAID space in addition to holding global leadership positions in the Anti-TB and Cephalosporin segments.

Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health), the only Asian company to achieve that distinction. The company is also the fastest growing top 10 pharmaceutical player in India, Japan and South Africa (IMS).

For the financial year ended March 2011, Lupin's Consolidated Revenues and Profit after Tax were Rs.57,068 Million (USD 1.28 Billion) and Rs. 8,626 Million (USD 193 Million) respectively. Please visit <http://www.lupinworld.com> for more information about Lupin Ltd.

### **About Lupin Pharmaceuticals, Inc.**

Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited. Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is committed to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visit <http://www.lupinpharmaceuticals.com>.

### **For more information, please contact:**

Shamsher Gorawara  
Head – Corporate Communications  
Lupin Limited:  
Ph: +91 98 20 338 555  
Email: [shamshergorawara@lupinpharma.com](mailto:shamshergorawara@lupinpharma.com)

*Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:*

*This release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release represents management's expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this release*

*\* SEROQUEL® Tablets are a registered trademark / copyright of AstraZeneca.*